Cartesian Therapeutics, INC 8-K filings

Cartesian Therapeutics announced strong Q2 2026 financial results, highlighting progress in its Descartes-08 clinical trials and a strategic partnership extending cash runway into 2028.

Cartesian Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.

Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to advance in vivo CAR-T therapies for autoimmune diseases, with a clinical trial planned for 2H 2026.

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, extending its cash runway into 2028 and supporting advancement of its cell therapy programs.

Cartesian Therapeutics announced first quarter 2026 financial results, highlighting progress in its Descartes-08 clinical trials for autoimmune diseases and a cash runway extending into mid-2027.

Cartesian Therapeutics highlights recent progress and outlines its 2026 strategic priorities for its mRNA cell therapy pipeline, including ongoing Phase 3 MG trial and new myositis and pediatric trials.

Cartesian Therapeutics strengthens its board with the appointment of Dr. Adrian Bot, a seasoned biopharma executive, and updates its Code of Business Conduct and Ethics.

Cartesian Therapeutics announced positive initial Phase 2 data for Descartes-08 in systemic lupus erythematosus and a strategic expansion into myositis, while pausing other programs to prioritize key autoimmune indications.

Cartesian Therapeutics announced Q3 2025 financial results, highlighting progress in its Phase 3 AURORA trial and a cash runway into mid-2027.

Cartesian Therapeutics announced leadership changes to its Board of Directors, with Carsten Brunn, Ph.D., taking over as Chairman following Carrie S. Cox's resignation.

Cartesian Therapeutics, Inc. announced the elimination of its Chief Scientific Officer position and the departure of Dr. Christopher Jewell, effective November 14, 2025.

Cartesian Therapeutics, Inc. announced the appointment of June Seymour as its new Chief Accounting Officer, effective October 27, 2025.

Cartesian Therapeutics reported Q2 2025 financial results and significant progress in its clinical pipeline, including the initiation of its pivotal Phase 3 AURORA trial for myasthenia gravis.

Cartesian Therapeutics, Inc. announced the successful election of three Class III Directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, a CAR-T cell therapy targeting myasthenia gravis, marking a significant advancement in its clinical development.

Cartesian Therapeutics announced its Q1 2025 financial results, reporting $182.1 million in cash and progress in its clinical trials, including the expected initiation of a Phase 3 trial for Descartes-08 in myasthenia gravis.

Cartesian Therapeutics, Inc. announced the departure of its Chief Technology Officer, Metin Kurtoglu, effective May 1, 2025, with a transition to a consulting role.

Cartesian Therapeutics reports sustained benefits and a favorable safety profile for Descartes-08 in myasthenia gravis patients after a single six-week course of treatment.

Cartesian Therapeutics announces its full year 2024 financial results, highlighting progress in its clinical trials and a strong cash position to support operations into mid-2027.

Cartesian Therapeutics is progressing its mRNA cell therapy pipeline, with a focus on autoimmune diseases and near-term catalysts including a Phase 3 trial for myasthenia gravis and data readouts for systemic lupus erythematosus.

Cartesian Therapeutics has received FDA agreement on the design of its Phase 3 trial for Descartes-08, a mRNA cell therapy for myasthenia gravis.

Cartesian Therapeutics is advancing its mRNA cell therapy pipeline, with a Phase 3 trial for Descartes-08 in myasthenia gravis expected to begin in the first half of 2025 and a Phase 2 SLE trial ongoing.

Cartesian Therapeutics reported positive updated results from its Phase 2b trial of Descartes-08 for myasthenia gravis, showing deepening and durable responses, and announced the design of its Phase 3 AURORA trial.

Cartesian Therapeutics reported its third quarter 2024 financial results and provided a business update, highlighting progress in its clinical programs and a strong cash position.

Cartesian Therapeutics' stockholders approved the issuance of common stock upon conversion of Series B preferred stock, resulting in 23,893,525 common shares outstanding.

Cartesian Therapeutics' stockholders approved the issuance of common stock upon conversion of Series B preferred stock and the adjournment of the special meeting if needed.

Cartesian Therapeutics reported positive topline results from its Phase 2b trial of Descartes-08 in myasthenia gravis, secured $130 million in financing, and is advancing its pipeline.

Cartesian Therapeutics announced a $130 million private placement and positive topline results from its Phase 2b trial of Descartes-08 in myasthenia gravis patients.

Cartesian Therapeutics held its 2024 Annual Meeting where stockholders approved an amended incentive plan, elected two Class II directors, and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Cartesian Therapeutics has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Descartes-08 therapy for myasthenia gravis.